ANTHONY C STEVENS

Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology BOSTON, MA NPI 1619933736

General Payments — all program years on this page

$17,412.50

  • Category: General Payments
  • Program years: PY2018
  • Record count: 14
  • As of (CMS publication): 2026-01-23

Latest program year (PY2018): $17,412.50 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2018) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $17,412.5014

By paying entity

Latest program year (PY2018) · sorted by reported total.

Paying entityAmountRecords
Incyte Corporation $14,012.5013
Keryx Biopharmaceuticals, Inc. $3,400.001

By program year

Program yearAmountRecords
2018 $17,412.5014

Records — PY2018 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
594019079 Incyte Corporation $1,662.50 06/27/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019087 Incyte Corporation $1,662.50 06/27/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019091 Incyte Corporation $475.00 08/01/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019098 Incyte Corporation $950.00 09/27/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019109 Incyte Corporation $2,137.50 09/27/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019117 Incyte Corporation $1,187.50 10/18/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019125 Incyte Corporation $712.50 10/31/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019130 Incyte Corporation $237.50 10/31/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019137 Incyte Corporation $1,662.50 10/31/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019143 Incyte Corporation $1,187.50 11/05/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019151 Incyte Corporation $712.50 11/08/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019155 Incyte Corporation $1,187.50 11/08/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
594019163 Incyte Corporation $237.50 12/19/2018 Consulting Fee Undisputed 01/23/2026 View at CMS
616458081 Keryx Biopharmaceuticals, Inc. $3,400.00 04/12/2018 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2018_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.